Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23941477 | 1.00 | ALOX5 (0.37) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL22863234 | 0.94 | ALOX5 (0.36) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL23941206 | 0.94 | ALOX5 (0.36) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL22863201 | 0.94 | ALOX5 (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL23941210 | 0.94 | ALOX5 (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL13746651 | 0.93 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL22863326 | 0.92 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL29406722 | 0.92 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL9880208 | 0.92 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL15744228 | 0.92 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | ALOX5 71/4885NR1H4 493/4885BACE1 754/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | ALOX5 117/4885NR1H4 342/4885BACE1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.